Oral versus intravenous cmf in metastatic breast-cancer - a randomized study.
Int J Oncol
; 4(3): 559-65, 1994 Mar.
Article
en En
| MEDLINE
| ID: mdl-21566959
ABSTRACT
Sixty-eight patients with previously untreated metastatic breast cancer were randomly assigned to receive either 'classical CMF' (orally administered cyclophosphamide) or new intravenous administration of all drugs every 3 weeks. Overall response rates of 44.5% (95% CI 28-62%) and 39% (95% CI24-54%) were observed with classical and new CMF, respectively. The time to progression and overall survival were also similar hematologic toxicity was mild in both groups, but the tolerance and patient compliance was generally better for the new CMF. The patients treated with classical CMF received a significantly higher drug intensity; dose intensity, however, had no impact on clinical results. In conclusion, our data suggest that the new CMF schedule has comparable activity to classical CMF but better patient compliance. A brief review of recent clinical studies regarding dose-effect relationships in breast cancer is included.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Int J Oncol
Asunto de la revista:
NEOPLASIAS
Año:
1994
Tipo del documento:
Article
País de afiliación:
Italia